Glaukos Q4 2020 Earnings Report
Key Takeaways
Glaukos Corporation reported Q4 2020 financial results with net sales increasing by 11% to $73.2 million compared to Q4 2019. The company's gross margin was approximately 73%, and non-GAAP gross margin was approximately 83%. The net loss for the quarter was $10.6 million, or ($0.24) per diluted share, compared to a net income of $36.6 million, or $0.84 per diluted share, in Q4 2019.
Net sales increased 11% to $73.2 million in Q4 2020 compared to $65.8 million in Q4 2019.
Glaucoma net sales reached $58.4 million, and Corneal Health net sales were $14.9 million in Q4 2020.
Gross margin was approximately 73%, and non-GAAP gross margin was approximately 83% in Q4 2020.
Operating expenses amounted to $65.0 million, with non-GAAP operating expenses at $61.5 million in Q4 2020.
Glaukos
Glaukos
Glaukos Revenue by Segment
Forward Guidance
The company expects the first quarter of 2021 net sales to increase approximately 15% to 20% compared to the first quarter of 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income